Vor Biopharma Inc. Common Stock (VOR) is a publicly traded Healthcare sector company. As of May 21, 2026, VOR trades at $15.35 with a market cap of $765.65M and a P/E ratio of -0.21. VOR moved +10.12% today. Year to date, VOR is +46.98%; over the trailing twelve months it is +335.57%. Its 52-week range spans $2.62 to $65.80. Analyst consensus is strong buy with an average price target of $33.80. Rallies surfaces VOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vor Bio Secures $491.5M Runway, Advances Phase 3 Telitacicept Trials with H1 2027 Data: Vor Bio ended Q1 2026 with $491.5M cash runway into early 2029 and recorded a $219.6M net loss driven by warrant fair-value changes, versus $32.5M a year earlier. Global Phase 3 trials of telitacicept in generalized myasthenia gravis and Sjögren’s disease are ongoing, with gMG topline data due H1 2027.
| Metric | Value |
|---|---|
| Price | $15.35 |
| Market Cap | $765.65M |
| P/E Ratio | -0.21 |
| EPS | $-70.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $65.80 |
| 52-Week Low | $2.62 |
| Volume | 996 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-695.98M |
| Gross Margin | 0.00% |
6 analysts cover VOR: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.80.